Adalimumab Uptake in the US (non-FDA session)
-
The approval of several Humira biosimilars (adalimumab) in late 2022 represented an opportunity for significant reductions in drug spending and potential savings for patients. Roughly one year later, are the savings coming to bear? In this session, representatives from payers, healthcare systems, pharmacy groups, and industry will discuss the obstacles to the initial uptake of adalimumab in the U.S. and what to expect next in this next phase of this landmark biosimilar and others following a similar path.
